|
 |
Nazwa handlowa |
|
|
Trade names are indicative and excipients composition can be different depending on the country and manufacturers
|
|
Camtoop |
Meksyk |
|
Cantop |
Indie |
|
Hycamtin |
Arabia Saudyjska, Australia, Austria, Belgia, Brazylia, Chile, Chorwacja, Dania, Egipt, Finlandia, Francja , Grecja, Hiszpania, Holandia, Irlandia, Islandia, Japonia, Kanada, KolumbiaKolumbia, Luksemburg, Malezja, Niemcy, Norwegia, Polska, Portugalia, Rumunia, Stany Zjednoczone Ameryki, Szwajcaria, Szwecja, Turcja, Węgry, Wenezuela, Wielka Brytania, Włochy, Zjednoczone Emiraty Arabskie |
|
Oncotecan |
Ekwador, KolumbiaKolumbia |
|
Potactasol |
Argentyna, Belgia, Chorwacja, Finlandia, Irlandia, Niemcy, Norwegia, Rumunia, Słowenia, Węgry, Włochy |
|
Topodria |
KolumbiaKolumbia |
|
Topokebir |
Argentyna |
|
Topotecan |
Argentyna, Belgia, Brazylia, Chile, Chorwacja, Finlandia, Francja , Hiszpania, Irlandia, Kanada, KolumbiaKolumbia, Niemcy, Norwegia, Peru, Rumunia, Szwajcaria, Szwecja, Węgry, Wielka Brytania, Włochy |
|
Topotel |
Egipt |
|
Toranex |
Meksyk |
|
Tpopoxin |
Turcja |
|
|
 |
 |
Bibliografia : Topotecan |
|
|
typ |
publikacja |
| 753 |
Laboratorium |
Topotecan (Topotecan Medac®) - Summary of Product Characteristics
Medac 2016 |
| 823 |
Czasopismo |
Patel K, Craig SB, McBride MG, Palepu NR.
Microbial inhibitory properties and stability of topotecan hydrochloride injection.
Am J Health-Syst Pharm 1998 ; 55: 1584-1587. |
| 1026 |
Czasopismo |
Mayron D, Gennaro AR.
Stability and compatibility of topotecan hydrochloride with selected drugs.
Am J Health-Syst Pharm 1999 ; 56: 875-881. |
| 1075 |
Czasopismo |
Craig SB, Bhatt UH, Patel K.
Stability and compatibility of topotecan hydrochloride for injection with common infusion solutions and containers.
J Pharm Biomed Anal 1997 ; 16: 199-205. |
| 1274 |
Czasopismo |
Krämer I, Thiesen J.
Pharmazeutische aspekte von topotecan-infusionen.
TAP Pharmazeutische Zeitung 1997 ; 31: 30-33. |
| 1423 |
Czasopismo |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1425 |
Czasopismo |
Krämer I, Thiesen J.
Stability of topotecan infusion solutions in polyvinylchloride bags and elastomeric portable infusion devices.
J Oncol Pharm Practice 1999 ; 5: 75-82. |
| 1662 |
Czasopismo |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37. |
| 1953 |
Czasopismo |
Trissel LA, Saenz CA, Ogundele AB, Ingram DS.
Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
| 1976 |
Czasopismo |
Trissel LA, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration.
Int J Pharm Compound 2005 ; 9, 3: 238-241. |
| 5157 |
Czasopismo |
Bello W, Hosotte C, Stampfli C, Pierrot A, Munier F L, Berger-Gryllaki M, Pezzatti J, Carrez L, Sadeghipour F.
Stability study of topotecan in ophthalmic prefilled syringes for intravitreal delivery
EJHP 2025 33:67-72 |
|
|
